Concepedia

Author

Georg Martin Haag

Heidelberg UniversityORCID

Also Known As

Carlo Fremd, G M Haag, G. Haag, G. M. Haag, G.M. Haag, Georg Haag, Georg M Haag, Georg M. Haag, Georg Martin Haag, Georg Martin Haag

117

Publications

6.6K

Citations

25

H-Index

41

Concepts

All Affiliations

Heidelberg UniversityUniversity Hospital HeidelbergNational Center for Tumor DiseasesUniversity Hospital FrankfurtGoethe University Frankfurt
GM

About

Georg Martin Haag is an author at Heidelberg University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

26

5.7K

2

Gastroenterology

16

16

5.2K

3

Pathology

13

15

1.4K

4

Immunology

6

6

240

5

Health Sciences

2

2

95

Georg Martin Haag

×

43

Publications

6.4K

Citations

24

H-Index

YearCitations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk,

The Lancet

2019

2.4K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk,

The Lancet Oncology

2016

713

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Salah‐Eddin Al‐Batran, Nils Homann, Harald Schmalenberg,

Journal of Clinical Oncology

2017

238

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer,

The Lancet Oncology

2023

175

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience,

Journal of Clinical Oncology

2023

173

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Susanne Blank, Thomas Schmidt, Patrick Heger,

Gastric Cancer

2017

100

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience,

Journal of Clinical Oncology

2022

94

Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial

Georg Martin Haag, Christoph Springfeld, Barbara Grün,

European Journal of Cancer

2022

86

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Ralf‐Dieter Hofheinz, Kirsten Merx, Georg Martin Haag,

Journal of Clinical Oncology

2022

86

Page 1